The Cancer Genetics Program's overall mission is to expand the understanding of the genetic underpinnings of cancer development, and to use this information to improve the care of cancer patients. To advance this mission, the Program has assembled a large and vibrant membership, including investigators with a broad range of scientific interests in all major aspects of cancer genetics, such as: cancer gene discovery in both human cancer samples and model organisms, technology development and efficient application of high throughput DNA sequencing, detailed cancer genome analysis, high throughput approaches to cancer gene analysis and annotation, identification and analysis of both cancer initiating cells and induced pluripotent stem cells, clinical cancer genetics and risk counseling, and development and use of CLIA-certified testing for clinically relevant cancer diagnostics.
The specific aims of the Program are to: 1. Support the discovery of new genes and cellular pathways implicated in cancer. 2. Enhance identification and understanding of the germline genetic variations that influence cancer risk and response to therapy. 3. Increase the understanding of the full spectrum of somatic mutation that occurs in cancer and how it contributes to the genesis and progression of cancer. 4. Support the translation of these research findings to both clinical research in oncology and routine cancer patient care. The Program has been funded by the CCSG since 2000 when DF/HCC was established, and received an """"""""Outstanding"""""""" merit score at the last renewal in 2005. The Program's membership includes 100 investigators, representing all seven institutions in the consortium, 14 departments of HMS, and one department of HSPH. In 2009, the Program received $52.5 million in cancer-relevant funding (total costs), which includes $18.5 million from NCI and $25 million from other peer-reviewed sponsors. Program members have published 1,630 publications over the project period (2006 to 2010), of which 9% were intra-programmatic, 44% were inter-programmatic and 32% were inter-institutional.

Public Health Relevance

The Cancer Genetics Program aims to expand the understanding of the genetic underpinnings of cancer development, and to use this information to improve the care of cancer patients. The Program brings together laboratory and clinical scientists to accelerate the translation of basic discoveries in genetics to the improvement of patient outcomes.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA006516-48
Application #
8469413
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2012-12-01
Budget End
2013-11-30
Support Year
48
Fiscal Year
2013
Total Cost
$84,981
Indirect Cost
$63,431
Name
Dana-Farber Cancer Institute
Department
Type
DUNS #
076580745
City
Boston
State
MA
Country
United States
Zip Code
02215
Agoston, Agoston T; Pham, Thai H; Odze, Robert D et al. (2018) Columnar-Lined Esophagus Develops via Wound Repair in a Surgical Model of Reflux Esophagitis. Cell Mol Gastroenterol Hepatol 6:389-404
Barber, Lauren; Gerke, Travis; Markt, Sarah C et al. (2018) Family History of Breast or Prostate Cancer and Prostate Cancer Risk. Clin Cancer Res 24:5910-5917
Kwee, Brian J; Budina, Erica; Najibi, Alexander J et al. (2018) CD4 T-cells regulate angiogenesis and myogenesis. Biomaterials 178:109-121
Madsen, Thomas; Braun, Danielle; Peng, Gang et al. (2018) Efficient computation of the joint probability of multiple inherited risk alleles from pedigree data. Genet Epidemiol 42:528-538
Chen, Jingjing; Guccini, Ilaria; Di Mitri, Diletta et al. (2018) Compartmentalized activities of the pyruvate dehydrogenase complex sustain lipogenesis in prostate cancer. Nat Genet 50:219-228
Li, Andrew G; Murphy, Elizabeth C; Culhane, Aedin C et al. (2018) BRCA1-IRIS promotes human tumor progression through PTEN blockade and HIF-1? activation. Proc Natl Acad Sci U S A 115:E9600-E9609
McBrayer, Samuel K; Mayers, Jared R; DiNatale, Gabriel J et al. (2018) Transaminase Inhibition by 2-Hydroxyglutarate Impairs Glutamate Biosynthesis and Redox Homeostasis in Glioma. Cell 175:101-116.e25
Stopsack, Konrad H; Gonzalez-Feliciano, Amparo G; Peisch, Samuel F et al. (2018) A Prospective Study of Aspirin Use and Prostate Cancer Risk by TMPRSS2:ERG Status. Cancer Epidemiol Biomarkers Prev 27:1231-1233
Kamareddine, Layla; Wong, Adam C N; Vanhove, Audrey S et al. (2018) Activation of Vibrio cholerae quorum sensing promotes survival of an arthropod host. Nat Microbiol 3:243-252
Schilit, Samantha L P; Morton, Cynthia C (2018) 3C-PCR: a novel proximity ligation-based approach to phase chromosomal rearrangement breakpoints with distal allelic variants. Hum Genet 137:55-62

Showing the most recent 10 out of 411 publications